Mercilon (Desogestrel, Ethinylestradiol)

Desogestrel suppresses the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation. Ethinylestradiol adds estrogenic activity that stabilises the endometrial lining and enhances the contraceptive effect while also thickening cervical mucus to impede sperm.

The specific dosing regimen for Mercilon is determined by the prescribing healthcare professional. Typically, it is taken as one tablet daily at the same time each day, but the exact schedule should follow the prescriber’s instructions.

Mercilon is contraindicated in pregnancy (Category X) and should not be started or continued if a woman becomes pregnant. It is generally not recommended during breastfeeding unless the benefits outweigh the risks, and a healthcare provider should be consulted.

To order Mercilon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mercilon contains desogestrel, a third‑generation progestogen, which may offer a lower risk of androgenic side effects compared with older progestins. Its estrogen component, ethinylestradiol 20 µg, is a standard dose, making its efficacy comparable to other combined pills while providing a favorable bleeding profile for many users.

Mercilon tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Mercilon is taken orally as a tablet. The usual practice is to swallow one tablet each day, preferably at the same time each day, with or without food, following the prescriber’s schedule.

The most serious risks include venous thromboembolism, arterial thrombosis (such as stroke or myocardial infarction), severe hypertension, and rare allergic reactions. Women with a history of clotting disorders, smoking, or certain cardiovascular conditions should discuss these risks with their healthcare provider.

Mercilon should not be used by women who are pregnant, have known or suspected estrogen‑dependent tumors, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or who are known to be hypersensitive to any of its components.